Navigation Links
Non-alcoholic steatohepataitis (NASH) Pipeline Analysis
Date:2/24/2017

NEW YORK, Feb. 23, 2017 /PRNewswire/ -- Non-alcoholic steatohepataitis (NASH) Pipeline Analysis" gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.

Read the full report: http://www.reportlinker.com/p04719470-summary/view-report.html

This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Non-alcoholic steatohepataitis (NASH) drugs market. The report also provide strategic insights on some of the molecules that are yet to be launched in the next few years.

Some of the key sections covered in the report are given below:
Epidemiology
In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.

Global & US prevalence rates
Hot Targets, Mechanisms & Therapies
In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis)

Market analysis
In market analysis section, global NASH drugs market is indicated along with the estimated Peak sales ($) of leading clinical stage drugs forecasted from 2019-2025.

Forecasting model for NASH market
NASH market dynamics
NASH Market and estimated Peak sales of 8 clinical candidates (OCA-Intercept, Aramchol-Galmed, GR-MD-02-Gilead, Cenicriviroc-Tobira, Simtuzumab-Gilead, Remo Biphasic-Avolynt, IVA 337-Inventiva Pharma, GFT505-Genfit)
NASH related deals analysis with financials (upfront, milestones and royalties)
Funding scenario in NASH market

Pipeline Analysis
Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development)

Pipeline analysis by modalities
Monoclonal Antibodies pipeline analysis
RNA-therapeutics pipeline analysis
Recombinant protein pipeline analysis
Pipeline analysis by leading players & Target analysis
Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic & Metabolic)

Key Players Analysis
The key player's analysis section provides an in-depth understanding of various companies working on Nonalcoholic steatohepatitis (NASH) and their Pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Global key players overview
Global key players Pipeline data (Discovery, Pre-clinical & Clinical development)
Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)

Read the full report: http://www.reportlinker.com/p04719470-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/non-alcoholic-steatohepataitis-nash-pipeline-analysis-300413100.html


'/>"/>
SOURCE Reportlinker
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Tobira Therapeutics Doses First Patient in CENTAUR, A Phase 2b Study of Cenicriviroc in Patients with Non-Alcoholic Steatohepatitis
2. Arcturus Therapeutics Announces Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH)
3. New Emergence of Potential Tx & Dx Options Predicted to Transform the Current Landscape for Liver Diseases (NASH) to a $35 Billion Opportunity
4. Global Nonalcoholic Steatohepatitis (NASH) Market (Pipeline analysis, drug class, clinical trials and Geography) - Research Report, 2013 - 2020
5. Dermatology Therapeutics Drug Development Pipeline Review, 2016: Approximately One-Third of the US Population Suffers from at Least One Active Skin Condition - Research and Markets
6. Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline
7. Phylogica Ltd - Product Pipeline Review - 2016
8. Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016
9. Quark Pharmaceuticals Inc - Product Pipeline Review - 2016
10. Ornithine-Transcarbamylase Deficiency - Pipeline Review, H2 2016
11. Wilson Disease - Pipeline Review, H2 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... (PRWEB) , ... August 10, 2018 , ... Dry eye ... Some of these products are excellent, and they do provide some relief from dry ... use than a product created and marketed by a small company in tiny Grants ...
(Date:8/11/2018)... SAN FRANCISCO (PRWEB) , ... August 11, 2018 ... ... Left Handers Day on Monday, August 13, with fun, games and gifts. Left-Handers ... in a world designed for right-handers. Having endured centuries of prejudice, countless indignities ...
(Date:8/9/2018)... ... 2018 , ... Autism is a developmental disorder affecting more than 3.5 million ... 1 in 68 people have the disorder), chances are you know someone on the ... child with autism methods of communication and tactics to interact with others. These options ...
Breaking Medicine Technology:
(Date:8/3/2018)... ... August 03, 2018 , ... Firstaid4sport ... Gerry Newlove first started the Firstaid4sport business in the 1990's and his son ... one of the leading providers in the UK of sports medicine products, supplying ...
(Date:8/3/2018)... ... August 03, 2018 , ... Lucyd Pte Ltd, ... announce the launch of its online store. The Lucyd eShop will feature the ... innovations in spectacles. , The eShop will have a number of unique ...
(Date:8/2/2018)... Calif. (PRWEB) , ... August 02, 2018 , ... ... be featuring its premium Resona 7 Ultrasound system with unique new upgrades at ... San Antonio, Texas. Based on ZONE Sonography® Technology (ZST), the upgrades include a ...
(Date:8/2/2018)... ... August 02, 2018 , ... A new ... topics in acute pain management. In The Role of Acute Care in the ... Engagement Network—an innovative approach to the opioid epidemic launched in the state of ...
(Date:8/2/2018)... ... ... Continuing their momentum in 2018 Sempulse has been selected as one of ... Ecliptic Capital, Mike W. Erwin, an early investor in Sempulse is bullish on the ... over 30 years starting companies and investing locally. The ideas, innovation and funding coming ...
Breaking Medicine News(10 mins):